About The Study
A milk allergy is one of the most common food allergies, with cow milk being the usual cause of a reaction. Symptoms of a milk allergy can be mild or severe, ranging from wheezing, vomiting, hives, and digestive upset, to a more severe reaction like anaphylaxis. Most will outgrow a milk allergy, but some may need to avoid milk products altogether.
Milk oral immunotherapy (OIT) can be used to desensitize patients with a milk allergy, but roughly a third of patients experience gastrointestinal side effects. Researchers are exploring whether adding dupilumab to oral immunotherapy (OIT) will enhance the safety and efficacy of OIT in patients with a milk allergy. All participants will receive milk OIT with either dupilumab or a placebo; a placebo looks like the study drug but contains no active medication.
Study Criteria
To qualify, participants must:
- Be between 4 and 50 years of age
- Have a diagnosed allergy to cow's milk or milk-containing products
- If allergic to multiple foods, eliminate all known food allergens from his or her diet during the study
Why Participate?
Qualified participants will receive the treatments of oral immunotherapy and half will receive the biologic dupilumab. There is no cost to participate and health insurance is not required to participate. Your participation is entirely voluntary.
